Comparing a Virtual vs. Face to Face Weight Management Program Using Phentermine for Patients With Overweight or Obesity

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will study the effects associated with the prescription of phentermine in a virtual setting, comparing with prescription of phentermine via a standard face-to-face visit for patients with obesity or overweight.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Cleveland Clinic
• Treatments: Phentermine

Criteria

Inclusion Criteria:

• Age 18-65 years old

• Body mass index (BMI) greater than or equal to 27 with 1 or more comorbidities (hypertension, diabetes, sleep apnea, fatty liver disease, PCOS, dyslipidemia, congestive heart failure, osteoarthritis) OR a BMI or 30 or greater

• Able to log into an online platform or have a smartphone

• Willing to join a virtual weight management program

Exclusion Criteria:

• Contraindication for use of phentermine

• Female who is pregnant, breast-feeding, or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods

• Participation in another clinical trial within 30 days of screening

• Cardiovascular disease including uncontrolled hypertension or history of arrhythmias

• Treatment with any medication with the intention of weight loss within 180 days before screening

• Use of Topiramate within 180 days of screening

• Previous history of bariatric surgery or use of minimally invasive weight loss devices